This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
This week on NephTrials we will discuss the PROTECT-V trial, a platform trial for preventing COVID-19 infections in the vulnerable kidney populations.
2023 brought us has dogma shredding data on hyponatremia and the importance of different diuretics. It has new therapies for old diseases like IgA and hypertension. New drugs for new diseases like inaxaplin for AMKD. And it has new data on old debates like what IVF is best and do thiazides really prevent kidney stones. It is a great list. Dig in!
Our NephJC NOSTONE editorial in Kidney Medicine is live. Great work from Renz Palisan, Nikita Pawar, and Rasha Alawieh; supported by Swap and Jade.
Read it here.
Our NephJC STOP-ACEi editorial in Kidney Medicine is live. Great work from Susan Thanabalasingam and Cristina Popa, supported by Nayan, Swap, and Jade.
Read it here.
The NephJC editorial in Kidney Medicine is live. Great work from Sheikh Khalid, Rachel Hung, and William Vasquez Espinosa, supported by Nayan, Joel, and Jamie.
Read it here.
Join #NephTwitter and have a drink with friends at the in-person NKF Spring Clinical Meeting in Boston this Friday. We are meeting at Summer Shack on Friday from 6 to 10 pm. The place is about a 1000 feet from the convention center at 50 Dalton Street.
